Word

RG

Status

Registered

Status Code

700

Status Date

Tuesday, June 11, 2024

Serial Number

90981041

Registration Number

7414310

Registration Date

Tuesday, June 11, 2024

Mark Type

3

Filing Date

Tuesday, August 24, 2021

Published for Opposition

Tuesday, August 23, 2022

Trademark Owner History

RinuaGene Biotechnology Co., Ltd. - Original Registrant

Classifications

5 Medical, biological, pharmaceutical, and veterinary preparations containing polypeptide encoding nucleic acids for the prevention and treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders;medical, biological, pharmaceutical, and veterinary preparations for medical and pharmaceutical use, namely, preparations for preventing and treating rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; RNA-based therapeutics and therapeutic agents for in vitro preparation and in vivo, ex vivo, or on vivo delivery to cell sites; cell-based immunotherapeutic treatment by way of genetically modified cells, medicated serums for the treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; attenuated viruses and particles similar to viruses, namely, encapsulated nucleic acids for the treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; diagnostic reagents and diagnostic preparations for medical purposes; chemical reagents used for medical or veterinary purposes; biochemical reagents used for medical or veterinary purposes for the treatment of cancer, treatment of immunological diseases, and treatment of infectious diseases; adjuvants for medical purposes; macromolecules, namely, nucleic acid sequences and proteins, used for medical and veterinary purposes; a full line of pharmaceuticals, vaccines, medicines, biologics, biotherapeutics, biosimilars and therapeutics for the treatment of infectious diseases and cancer; vaccines; a full line of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics for the treatment of infectious diseases and cancer

The mark consists of a stylized illustration of the letters "R" and "G", which illustration is also meant to be a stylized presentation of the DNA double helix structure.

Trademark Events

Aug 27, 2021

New Application Entered

Oct 10, 2021

New Application Office Supplied Data Entered

Oct 12, 2021

Notice Of Design Search Code E-Mailed

May 26, 2022

Assigned To Examiner

Jun 9, 2022

Non-Final Action Written

Jun 9, 2022

Notification Of Non-Final Action E-Mailed

Jun 9, 2022

Non-Final Action E-Mailed

Jul 15, 2022

Teas Withdrawal Of Attorney Received

Jul 15, 2022

Withdrawal Of Attorney Granted

Jul 15, 2022

Teas Response To Office Action Received

Jul 15, 2022

Teas Response To Office Action Received

Jul 15, 2022

Teas/Email Correspondence Entered

Jul 15, 2022

Correspondence Received In Law Office

Jul 18, 2022

Approved For Pub - Principal Register

Aug 3, 2022

Notification Of Notice Of Publication E-Mailed

Aug 23, 2022

Published For Opposition

Aug 23, 2022

Official Gazette Publication Confirmation E-Mailed

Oct 18, 2022

Noa E-Mailed - Sou Required From Applicant

Mar 20, 2023

Sou Teas Extension Received

Mar 20, 2023

Sou Extension 1 Filed

Mar 20, 2023

Sou Extension 1 Granted

Mar 20, 2023

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Mar 20, 2023

Attorney/Dom.Rep.Revoked And/Or Appointed

Mar 20, 2023

Teas Change Of Correspondence Received

Mar 22, 2023

Notice Of Approval Of Extension Request E-Mailed

Apr 17, 2023

Teas Change Of Owner Address Received

Apr 17, 2023

Teas Change Of Correspondence Received

Apr 17, 2023

Applicant/Correspondence Changes (Non-Responsive) Entered

Oct 4, 2023

Assigned To Examiner

Oct 11, 2023

Sou Teas Extension Received

Oct 11, 2023

Sou Extension 2 Filed

Oct 11, 2023

Sou Extension 2 Granted

Oct 13, 2023

Notice Of Approval Of Extension Request E-Mailed

Apr 12, 2024

Sou Extension 3 Filed

Apr 12, 2024

Divisional Request Received

Apr 12, 2024

Use Amendment Filed

Apr 12, 2024

Sou Teas Extension Received

Apr 12, 2024

Teas Request To Divide Received

Apr 12, 2024

Teas Statement Of Use Received

Apr 23, 2024

Case Assigned To Intent To Use Paralegal

May 8, 2024

Sou Extension 3 Granted

May 8, 2024

Divisional Processing Complete

May 8, 2024

Statement Of Use Processing Complete

May 9, 2024

Notice Of Acceptance Of Statement Of Use E-Mailed

May 9, 2024

Allowed Principal Register - Sou Accepted

May 9, 2024

Notice Of Approval Of Extension Request E-Mailed

May 9, 2024

Notice Of Design Search Code E-Mailed

Jun 11, 2024

Registered-Principal Register

Jun 11, 2024

Notice Of Registration Confirmation Emailed